MGuard Stent in ST-elevation Myocardial Infarction (GUARDIAN)

March 15, 2022 updated by: Giovanni Esposito, Federico II University

MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial

The Investigators will test the hypothesis that MGuard net protective stent, the investigational device, would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent percutaneous coronary interventions.

Study Overview

Detailed Description

Embolization of thrombotic debris still represents a complication for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventions (PCI).

Distal embolization may decrease coronary and myocardial reperfusion after PCI in STEMI setting.

Unfortunately, intracoronary filters present several important limitations limiting their use and their efficacy especially in presence of huge amount of thrombus. In this respect, recent trials investigated whether a default manual thrombectomy strategy before stenting would ameliorate angiographic as well as clinical outcomes for STEMI patients undergoing percutaneous revascularization.

Of note, the most of embolization occurs when guidewire, and thrombectomy device cross the thrombus, and after the stent has been implanted as a consequence of plaque prolapse through the stent struts.

MGuard net protective stent, the investigational device, is a bare-metal stent covered with a ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, that is anchored to the external surface of the struts. This biocompatible fiber net (string diameter 10-22 μm) has minimal effects on the stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net and isolating the prothrombotic intima components from the blood stream.

This protocol will test the hypothesis that MGuard stent would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent PCI in terms of angiographic as well as clinical outcomes.

Study Type

Interventional

Enrollment (Actual)

350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Naples, Italy, 80131
        • Federico II University of Naples

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • >/= 18-year-old patients, willing to participate the study, after informed consent signature
  • Female not pregnant or potentially child-bearing
  • > 1 mV ST segment elevation in two or more contiguous leads
  • Acute MI lasting more than 30 minutes and less than 12 hours
  • De novo acute MI
  • Infarct related artery reference vessel diameter >/= 2.5 mm
  • Patient suitable for stenting according to vessel and lesion features

Exclusion Criteria:

  • Dual antiplatelet therapy contraindication
  • Ischemic stroke less than 30 days or previous haemorrhagic stroke
  • WBC count less than 1000 per mm3;
  • Platelet count less than 50.000 per mm3
  • Life expectancy less than 1 year
  • Cardiogenic shock at admission
  • Previous stented infarct related artery
  • Stent thrombosis as the responsible for current STEMI
  • Inability to identify infarct related artery
  • True bifurcation lesion, or lesion near a side branch with a reference vessel diameter >/= 2.5 mm that could be diseased after stenting procedure
  • LBBB
  • Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation
  • Participation other study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MGuard
MGuard net protective stent, investigational device
It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
Other Names:
  • MGuard net protective stent
Active Comparator: BMS plus thrombectomy
Bare-metal stent plus manual thrombectomy device
Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with Myocardial Perfusional Blush Grade 2-3
Time Frame: 30 minutes after revascularization
Myocardial Perfusional Blush Grade 2-3 at the end of the procedure
30 minutes after revascularization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of MACE
Time Frame: 1 month
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
1 month
Complete ST-segment resolution
Time Frame: 60 minutes after revascularization
Complete (>70%) ST-segment resolution at 60 minutes post-revascularization
60 minutes after revascularization
Thrombolysis in myocardial infarction antegrade coronary flow
Time Frame: 30 minutes after revascularization
TIMI coronary flow at the end of the procedure
30 minutes after revascularization
Corrected TIMI Frame count
Time Frame: 30 minutes after revascularization
Corrected TIMI Frame count at the end of the procedure
30 minutes after revascularization
Infarct related area reduction and left ventricular ejection fraction recovery
Time Frame: 6 months
Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission.
6 months
Procedural device performance
Time Frame: 60 minutes after revascularizationl
Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability
60 minutes after revascularizationl
Number of MACE
Time Frame: 6 months
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
6 months
Number of MACE
Time Frame: 12 months
Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Federico Piscione, Associate Professor, Federico II University of Naples

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2010

Primary Completion (Actual)

March 1, 2011

Study Completion (Actual)

March 1, 2013

Study Registration Dates

First Submitted

April 8, 2010

First Submitted That Met QC Criteria

May 17, 2010

First Posted (Estimate)

May 18, 2010

Study Record Updates

Last Update Posted (Actual)

March 31, 2022

Last Update Submitted That Met QC Criteria

March 15, 2022

Last Verified

March 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ST-elevation Myocardial Infarction

Clinical Trials on MGuard net protective coronary stent

3
Subscribe